Drugs / TG-1000
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04495322 | Jul → Nov 2020 | — | TaiGen Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04706468 | Dec 2020 → Feb 2022 | influenza | TaiGen Biotechnology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TG-1000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04495322 ↗ |
| Route | Oral | “single oral dose of TG-1000” NCT04495322 ↗ |